ArticleDrug design, development and therapy2026
L-Citrulline Attenuates Keratinocyte Activation and Modulates ASS1 Expression in Psoriasis-Like Mice.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Psoriasis is a common chronic inflammatory skin disease with a high prevalence, which seriously impairs patients' quality of life. Although the clinical application of biologics has achieved satisfactory therapeutic effects, it still has certain limitations, such as high recurrence rate and poor clinical response in some patients. Therefore, it is urgent to further explore the pathogenesis of psoriasis to identify novel research directions and therapeutic targets for the prevention and treatment of this disease. Methods: An imiquimod (IMQ)-induced psoriasis-like mouse model was established in this study. Multi-omics profiling and molecular biological experiments were performed to explore the regulatory mechanism underlying psoriasis progression. Keratinocyte functional assays and pharmacological intervention were conducted to verify the biological function of L-citrulline and ASS1. Results: L-citrulline levels were significantly decreased in the lesional skin of psoriatic mice. L-citrulline treatment substantially alleviated psoriasis-like pathological phenotypes and restrained keratinocyte hyperactivation, including excessive proliferation, migration, and inflammatory responses. Mechanistically, L-citrulline markedly downregulated the expression of ASS1, which was highly upregulated in psoriatic skin lesions. Functional validation demonstrated that ASS1 overexpression promoted keratinocyte activation, whereas pharmacological inhibition of ASS1 efficiently suppressed keratinocyte hyperactivation in vitro and ameliorated IMQ-induced psoriasis-like skin lesions in vivo. Conclusion: ASS1 serves as a critical regulator and promising therapeutic target for psoriasis. L-citrulline supplementation or ASS1 inhibition effectively blocks keratinocyte hyperactivation and retards psoriasis progression, providing a novel and feasible therapeutic strategy for psoriasis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.